4.7 Article

Tumor Infiltration by T Lymphocytes Expressing Chemokine Receptor 7 (CCR7) Is Predictive of Favorable Outcome in Patients with Advanced Colorectal Carcinoma

期刊

CLINICAL CANCER RESEARCH
卷 18, 期 3, 页码 850-857

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-10-3186

关键词

-

类别

资金

  1. Italian Ministry of Scientific Research (MIUR)

向作者/读者索取更多资源

Purpose: An efficient adaptive immunity is critical for a longer survival in cancer. We investigated the prognostic value of tumor infiltration by CD8(+) T cells expressing the chemokine-receptor-7 (T-ccr7) and the correlation between tumor infiltration by T-ccr7 and regulatory CD4(+)FoxP3(+) T cells (T-reg) in 76 metastatic colorectal cancer (mCRC) patients enrolled in a phase III trial. Experimental Design: T-ccr7 and T-reg cell infiltration in tumor samples was quantified by immunohistochemistry. The correlation among T-ccr7, T-reg tumor infiltration, and patients' outcome was evaluated. Results: High T-ccr7 tumor infiltration was predictive of prolonged OS [high vs. low T-ccr7 score: median 38 months (95% Cl: 24.5-51.4) vs. 20 months (95% Cl: 11.4-28.5); HR = 0.48 (95% Cl: 0.24-0.96); P=0.03] and prolonged progression-free survival [ITS; high vs. low T-ccr7 score: median 12 months (95% Cl: 7.7-16.2) vs. 7 months (95% Cl: 5.2-8.7); HR = 0.54 (95% Cl: 0.28-1.01); P = 0.01] after front-line chemotherapy. Regression analysis did not show correlation between T-ccr7 and T-reg infiltration levels. However, the cluster of patients showing concomitant high infiltration by both T-ccr7 and T-reg disclosed a favorable outcome [double high vs. double low tumor infiltration score: median OS = 35 months (95% Cl: 20.8-49.1) vs. 17 months (95% Cl: 4.6-29.3); HR = 0.32(95% Cl: 0.12-0.87); P = 0.02 and median PFS = 11 months (95% CI: 9.4-12.5) vs. 5 months (95% Cl: 2.2-7.7); HR = 0.43 (95% Cl: 0.17-1.06); P = 0.01]. Conclusions: High T-ccr7 tumor infiltration score is a favorable prognostic factor for mCRC. Our findings underline the relevance of microenvironment-related immunologic events for patient outcome. Clin Cancer Res; 18(3); 850-7. (C) 2011 AACR.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Hematology

FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology

Cirino Botta, Catarina Maia, Juan-Jose Garces, Rosalinda Termini, Cristina Perez, Irene Manrique, Leire Burgos, Aintzane Zabaleta, Diego Alignani, Sarai Sarvide, Juana Merino, Noemi Puig, Maria-Teresa Cedena, Marco Rossi, Pierfrancesco Tassone, Massimo Gentile, Pierpaolo Correale, Ivan Borrello, Evangelos Terpos, Tomas Jelinek, Artur Paiva, Aldo Roccaro, Hartmut Goldschmidt, Herve Avet-Loiseau, Laura Rosinol, Maria-Victoria Mateos, Joaquin Martinez-Lopez, Juan-Jose Lahuerta, Joan Blade, Jesus F. San-Miguel, Bruno Paiva

Summary: Large-scale immune monitoring is increasingly used in clinical trials, but manual interpretation of multidimensional data poses challenges. FlowCT is a semi-automated workspace that can analyze large datasets, including preprocessing, normalization, dimensionality reduction, clustering, and predictive modeling tools.

BLOOD ADVANCES (2022)

Article Oncology

Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials

Enrica Antonia Martino, Concetta Conticello, Elena Zamagni, Vincenzo Pavone, Salvatore Palmieri, Maurizio Musso, Paola Tacchetti, Anna Mele, Lucio Catalano, Ernesto Vigna, Antonella Bruzzese, Francesco Mendicino, Cirino Botta, Iolanda Donatella Vincelli, Giuliana Farina, Marialucia Barone, Clotilde Cangialosi, Katia Mancuso, Ilaria Rizziello, Serena Rocchi, Antonietta Pia Falcone, Giuseppe Mele, Giovanni Reddiconto, Bruno Garibaldi, Enrico Iaccino, Giovanni Tripepi, Barbara Gamberi, Francesco Di Raimondo, Pellegrino Musto, Antonino Neri, Michele Cavo, Fortunato Morabito, Massimo Gentile

Summary: This study presents a retrospective multicenter analysis of 600 relapsed and refractory multiple myeloma patients treated with KRd therapy, revealing the safety and efficacy of KRd in clinical practice. Factors such as creatinine clearance<30 ml/min, >1 line of previous therapy, and high-risk FISH are associated with poor prognosis.

HEMATOLOGICAL ONCOLOGY (2022)

Article Oncology

PD-1/PD-L1 immune-checkpoint blockade induces immune effector cell modulation in metastatic non-small cell lung cancer patients: A single-cell flow cytometry approach

Antonella Fameli, Valerio Nardone, Mojtaba Shekarkar Azgomi, Giovanna Bianco, Claudia Gandolfo, Bianca Maria Oliva, Marika Monoriti, Rita Emilena Saladino, Antonella Falzea, Caterina Romeo, Natale Daniele Calandruccio, Domenico Azzarello, Rocco Giannicola, Luigi Pirtoli, Antonio Giordano, Pierfrancesco Tassone, Pierosandro Tagliaferri, Maria Grazia Cusi, Luciano Mutti, Cirino Botta, Pierpaolo Correale

Summary: Peripheral immune-checkpoint blockade with PD-1/PD-L1 antibodies is a promising treatment strategy for mNSCLC patients. This study investigates the impact of PD-1/PD-L1 blockade on specific immune cell subsets and suggests a correlation between immune subpopulation deregulation and autoimmunity.

FRONTIERS IN ONCOLOGY (2022)

Editorial Material Medicine, Research & Experimental

Analysis of new treatments proposed for malignant pleural mesothelioma raises concerns about the conduction of clinical trials in oncology

Tomer Meirson, Valerio Nardone, Francesca Pentimalli, Gal Markel, David Bomze, Maria D'Apolito, Pierpaolo Correale, Antonio Giordano, Luigi Pirtoli, Camillo Porta, Steven G. Gray, Luciano Mutti

Summary: In this article, the authors emphasize the importance of finding the appropriate balance between the financial impact and actual patient benefit of new cancer drugs. Taking pleural mesothelioma as an example, the authors analyze the existing clinical trial data and raise concerns regarding trial design, biomarker-based stratification, and the need to balance the benefit/cost ratio for both patients and healthcare providers.

JOURNAL OF TRANSLATIONAL MEDICINE (2022)

Article Biochemistry & Molecular Biology

Molecular-Biology-Driven Frontline Treatment for Chronic Lymphocytic Leukemia: A Network Meta-Analysis of Randomized Clinical Trials

Andrea Rizzuto, Angelo Pirrera, Emilia Gigliotta, Salvatrice Mancuso, Candida Vullo, Giulia Maria Camarda, Cristina Rotolo, Arianna Roppolo, Corinne Spoto, Massimo Gentile, Cirino Botta, Sergio Siragusa

Summary: The current treatment for chronic lymphocytic leukemia (CLL) relies on chemotherapy, immunotherapy, and targeted inhibitors. However, the multitude of choices and lack of direct comparisons make treatment selection challenging. To address this, a systematic review and meta-analysis of clinical trials in CLL were performed. The results showed that a combination of obinutuzumab with acalabrutinib was the most effective treatment, especially in the absence of del17/P53 mutations. Additionally, chemotherapy is becoming less relevant in the first-line treatment of CLL.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Biochemistry & Molecular Biology

Ferritin Metabolism Reflects Multiple Myeloma Microenvironment and Predicts Patient Outcome

Federica Plano, Emilia Gigliotta, Anna Maria Corsale, Mojtaba Shekarkar Azgomi, Carlotta Santonocito, Manuela Ingrasci, Laura Di Carlo, Antonino Elia Augello, Maria Speciale, Candida Vullo, Cristina Rotolo, Giulia Maria Camarda, Nadia Caccamo, Serena Meraviglia, Francesco Dieli, Sergio Siragusa, Cirino Botta

Summary: Multiple myeloma (MM) is a hematologic malignancy characterized by a pro-inflammatory and immunosuppressive microenvironment. Ferritin, released by pro-inflammatory cells, contributes to ROS production and cellular damage. The study found that high ferritin levels were associated with worse prognosis in MM patients and correlated with systemic inflammation markers and specific bone marrow cell microenvironment. Bioinformatic analysis also revealed that ferritin biosynthesis gene expression signature was associated with poor outcome and specific immune cell profiles. These findings suggest that ferritin could be a potential target for improving MM patient outcome.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Biochemistry & Molecular Biology

B-Cell Receptor Signaling Is Thought to Be a Bridge between Primary Sjogren Syndrome and Diffuse Large B-Cell Lymphoma

Leila Mohammadnezhad, Mojtaba Shekarkar Azgomi, Marco Pio La Manna, Giuliana Guggino, Cirino Botta, Francesco Dieli, Nadia Caccamo

Summary: This study identified new signaling pathways in the progression of primary Sjogren syndrome (pSS) to diffuse large B-cell lymphoma (DLBCL) and discovered CD79A, CD79B, and LAMTOR4 as potential novel biomarkers for pSS progression into lymphoma.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Biochemistry & Molecular Biology

Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma

Marta Larrayoz, Maria J. Garcia-Barchino, Jon Celay, Amaia Etxebeste, Maddalen Jimenez, Cristina Perez, Raquel Ordonez, Cesar Cobaleda, Cirino Botta, Vicente Fresquet, Sergio Roa, Ibai Goicoechea, Catarina Maia, Miren Lasaga, Marta Chesi, P. Leif Bergsagel, Maria J. Larrayoz, Maria J. Calasanz, Elena Campos-Sanchez, Jorge Martinez-Cano, Carlos Panizo, Paula Rodriguez-Otero, Silvestre Vicent, Giovanna Roncador, Patricia Gonzalez, Satoru Takahashi, Samuel G. Katz, Loren D. Walensky, Shannon M. Ruppert, Elisabeth A. Lasater, Maria Amann, Teresa Lozano, Diana Llopiz, Pablo Sarobe, Juan J. Lasarte, Nuria Planell, David Gomez-Cabrero, Olga Kudryashova, Anna Kurilovich, Maria V. Revuelta, Leandro Cerchietti, Xabier Agirre, Jesus San Miguel, Bruno Paiva, Felipe Prosper, Jose A. Martinez-Climent

Summary: The lack of preclinical models reflecting the genetic heterogeneity of multiple myeloma (MM) has hindered therapeutic discoveries. To overcome this limitation, researchers used genetically engineered mice to develop bone marrow tumors that mimic MM pathogenesis. Integrative analyses of mice and patients revealed a common genetic pathway that accelerates disease progression and immune evasion mechanisms that remodel the bone marrow microenvironment differently.

NATURE MEDICINE (2023)

Article Cell Biology

Iron-mediated oxidative stress induces PD-L1 expression via activation of c-Myc in lung adenocarcinoma

Anna Martina Battaglia, Alessandro Sacco, Ilenia Aversa, Gianluca Santamaria, Camillo Palmieri, Cirino Botta, Roberto De Stefano, Maurizio Bitetto, Lavinia Petriaggi, Emanuele Giorgio, Concetta Maria Faniello, Francesco Costanzo, Flavia Biamonte

Summary: In this study, the relationship between iron density in the tumor microenvironment (TME) and PD-L1 expression in lung adenocarcinoma (LUAD) was investigated. It was found that higher iron levels were associated with increased expression of PD-L1. This suggests that iron abundance within the TME may potentially be a target for improving the outcomes of LUAD patients treated with anti-PD-1/PD-L1 therapies.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2023)

Article Multidisciplinary Sciences

Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance

Cirino Botta, Cristina Perez, Marta Larrayoz, Noemi Puig, Maria-Teresa Cedena, Rosalinda Termini, Ibai Goicoechea, Sara Rodriguez, Aintzane Zabaleta, Aitziber Lopez, Sarai Sarvide, Laura Blanco, Daniele M. Papetti, Marco S. Nobile, Daniela Besozzi, Massimo Gentile, Pierpaolo Correale, Sergio Siragusa, Albert Oriol, Maria Esther Gonzalez-Garcia, Anna Sureda, Felipe de Arriba, Rafael Rios Tamayo, Jose-Maria Moraleda, Mercedes Gironella, Miguel T. Hernandez, Joan Bargay, Luis Palomera, Albert Perez-Montana, Hartmut Goldschmidt, Herve Avet-Loiseau, Aldo Roccaro, Alberto Orfao, Joaquin Martinez-Lopez, Laura Rosinol, Juan-Jose Lahuerta, Joan Blade, Maria-Victoria Mateos, Jesus F. San-Miguel, Jose-Angel Martinez Climent, Bruno Paiva

Summary: T cell recognition of tumors is crucial for antitumor immunity. In this study, single-cell RNA and T cell receptor sequencing were used to analyze bone marrow T cells in patients with multiple myeloma. The findings suggest that large T cell clones in multiple myeloma patients exhibit dysfunctional phenotypes and express multiple immune checkpoints. Dual targeting of specific immune checkpoints partially restored the function of these T cells.

NATURE COMMUNICATIONS (2023)

Review Oncology

Lynch Syndrome Biopathology and Treatment: The Potential Role of microRNAs in Clinical Practice

Serena Ascrizzi, Grazia Maria Arillotta, Katia Grillone, Giulio Carida, Stefania Signorelli, Asad Ali, Caterina Romeo, Pierfrancesco Tassone, Pierosandro Tagliaferri

Summary: Lynch syndrome, also known as Hereditary Non-Polyposis Colorectal Cancer (HNPCC), is an autosomal dominant cancer syndrome that poses a high risk of developing colorectal and endometrial cancer. The molecular mechanisms underlying Lynch syndrome, including microsatellite instability and miRNA modulation, have attracted significant interest. This review discusses the management of Lynch syndrome patients and highlights the importance of microRNAs as potential biomarkers and therapeutic targets for novel clinical approaches.

CANCERS (2023)

Review Multidisciplinary Sciences

First-line systemic treatment for hepatocellular carcinoma: A systematic review and network meta-analysis

Domenico Ciliberto, Giulio Carid, Nicoletta Staropoli, Caterina Romeo, Grazia Maria Arillotta, Cristina Napoli, Luigia Gervasi, Francesco Luciano, Caterina Riillo, Pierfrancesco Tassone, Pierosandro Tagliaferri

Summary: The rational choice of systemic upfront treatment for advanced hepatocellular carcinoma has become uncertain due to the rapid development of novel therapeutic options. Various therapeutic strategies, including the combination of immune checkpoint inhibitors and anti-VEGF, have been investigated. A systematic review and meta-analysis of randomized clinical trials were conducted to compare the efficacy and toxicity of these strategies. The combination of Camrelizumab + Rivoceranib ranked highest in overall survival, followed by Sintilimab + Bevacizumab, while Lenvatinib + Pembrolizumab showed greater probability of being the best in progression-free survival and Sintilimab + Bevacizumab performed best in overall response rate. Durvalumab was found to be the most tolerated treatment.

HELIYON (2023)

Review Hematology

Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again

Federica Plano, Anna Maria Corsale, Emilia Gigliotta, Giulia Camarda, Candida Vullo, Marta Di Simone, Mojtaba Shekarkar Azgomi, Maria Speciale, Melania Carlisi, Nadia Caccamo, Francesco Dieli, Serena Meraviglia, Sergio Siragusa, Cirino Botta

Summary: Multiple myeloma (MM) is an incurable hematologic malignancy with a multistep evolutionary pathway, involving monoclonal gammopathy of undetermined significance (MGUS), smoldering MM (sMM), and symptomatic MM. Genomic alterations are present at the MGUS phase, but their role in disease evolution is questionable. Changes in the bone marrow microenvironment (TME) play a key role in MM evolution, driving cancer progression and clonal plasma cell behavior. Microenvironment-oriented drugs have significantly improved MM patients' survival. This review discusses the role of the TME in MM evolution and potential therapeutic targets/opportunities.

HEMATOLOGY REPORTS (2023)

Review Radiology, Nuclear Medicine & Medical Imaging

The role of brain radiotherapy for EGFR- and ALK-positive non-small-cell lung cancer with brain metastases: a review

Valerio Nardone, Caterina Romeo, Emma D'Ippolito, Pierpaolo Pastina, Maria D'Apolito, Luigi Pirtoli, Michele Caraglia, Luciano Mutti, Giovanna Bianco, Antonella Consuelo Falzea, Rocco Giannicola, Antonio Giordano, Pierosandro Tagliaferri, Claudia Vinciguerra, Isacco Desideri, Mauro Loi, Alfonso Reginelli, Salvatore Cappabianca, Pierfrancesco Tassone, Pierpaolo Correale

Summary: Non-small cell lung cancer (NSCLC) patients often experience complications from central nervous system (CNS) metastases, which greatly impact their life expectancy and quality of life. Current clinical trials involving neurosurgery, radiotherapy (RT), and systemic treatments have yielded conflicting results. CNS involvement is more frequent in NSCLC patients with EGFR activating mutations or ALK rearrangement, suggesting the potential role of targeted therapy as the initial treatment instead of local therapies such as RT or surgery. However, the use of accurate brain imaging, such as MRI, to identify patients who could benefit from local therapies has not been extensively studied in clinical research. Additionally, there are no clear guidelines on the timing of intervention with regards to innovative precision medicine approaches when concomitant RT is required. This review aims to discuss therapeutic strategies that integrate medical and radiation oncology in patients with metastatic NSCLC (mNSCLC) adenocarcinoma with CNS involvement and specific genetic mutations.

RADIOLOGIA MEDICA (2023)

Review Oncology

Multiple Myeloma in 2023 Ways: From Trials to Real Life

Manlio Fazio, Vittorio Del Fabro, Nunziatina Laura Parrinello, Alessandro Allegra, Uros Markovic, Cirino Botta, Fabrizio Accardi, Iolanda Donatella Vincelli, Salvatore Leotta, Federica Elia, Benedetta Esposito, Bruno Garibaldi, Gabriele Sapuppo, Alessandra Orofino, Alessandra Romano, Giuseppe A. Palumbo, Francesco Di Raimondo, Concetta Conticello

Summary: This article reviews the current treatment regimens for multiple myeloma, compares clinical trials with real-life experiences, and highlights promising therapies such as T-cell engagers and chimeric antigen receptor T-cells (CAR-T) that are effective in changing the course of advanced-stage disease.

CURRENT ONCOLOGY (2023)

暂无数据